Background: Pneumonia is one of the causes of death in infants in developing countries especially Indonesia. Appropriate treatment is needed to decrease mortality rate in children due to pneumonia. Ampicillin is one of first choices empirical antibiotic to children with severe pneumonia. The study was aimed to determine the failure rate of ampicillin in children with severe pneumonia. Methods: This study was a descriptive study which used medical records as source of data. Subjects were children aged 2-59 months with World Health Organization (WHO) defined with severe pneumonia and treated with intravenous ampicillin during January 2014 to July 2015 at Dr. Hasan Sadikin General Hospital Bandung. Samples were obtained using total sampling method while variables were analyzed using statistics software. Results: This study acquired 107 patients who met the inclusion criteria with 23.36% of them aged 2-11 months and 62.21% aged 12-23 months. Majority of subjects were male amounted as 63.55% while female occupied 36.45%. Treatment failure on the third day was 45.8% while 16.7% on the sixth day of therapy with majority failure due to existence of lower chest indrawing. Conclusions: Treatment failure on the third and sixth day of therapy still high that is characterized by the existence of lower chest indrawing as its main factor. [AMJ.2017;4(1):100-6]
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.